Loibl S, Untch M, Burchardi N, Huober J, et al. Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Onco Ann Oncol 2022 May 17. pii: S0923-7534(22)00676.
PMID: 35595658